RESUMO
This comprehensive review on opioids summarizes the scope of the current opioid epidemic, the diagnosis and treatment of opioid use disorder, and the medical and psychiatric complications of opioid use.
Assuntos
Analgésicos Opioides/efeitos adversos , Overdose de Drogas/prevenção & controle , Transtornos Relacionados ao Uso de Opioides/diagnóstico , Transtornos Relacionados ao Uso de Opioides/terapia , Guias de Prática Clínica como Assunto/normas , Adulto , Buprenorfina/farmacologia , Buprenorfina/uso terapêutico , Comorbidade , Gerenciamento Clínico , Overdose de Drogas/mortalidade , Feminino , Fentanila/farmacologia , Fentanila/uso terapêutico , Redução do Dano/efeitos dos fármacos , Humanos , Masculino , Transtornos Mentais/epidemiologia , Transtornos Mentais/etiologia , Metadona/farmacologia , Metadona/uso terapêutico , Pessoa de Meia-Idade , Naltrexona/farmacologia , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/farmacologia , Antagonistas de Entorpecentes/uso terapêutico , Entorpecentes/farmacologia , Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/complicações , Transtornos Relacionados ao Uso de Opioides/epidemiologia , PrevalênciaRESUMO
BACKGROUND: Opioid overdose prevention education and naloxone distribution (OEND) programs include information on general risk factors, overdose recognition, and naloxone utilization. This study evaluated a personally-tailored OEND (PTOEND) intervention designed to promote harm reduction and treatment readiness for illicit opioid users by also including education about personal overdose-risk factors and medication for opioid use disorder (MOUD). METHOD: A secondary analysis of a randomized controlled trial testing a Peer recovery support service (PRSS) intervention, relative to Control, in adult illicit opioid users reporting treatment for an overdose in the prior 6 months. PTOEND, a 30-minute computer-guided intervention, was administered by a research assistant at the randomization visit to all participants (N = 80). Participants completed a telephone visit 3 weeks post-randomization (n = 74) to assess changes in opioid overdose/MOUD knowledge and treatment readiness. Participants completed in-person visits at 3 (n = 66), 6 (n = 58), and 12 (n = 44) months post-randomization to assess illicit opioid use and naloxone utilization (all time points) and overdose-risk behaviors (12 months). We conducted pre-post analyses of the impact of PTOEND controlling for the PRSS effect. RESULTS: PTOEND increased knowledge of overdose (79.8% to 81.5%, p < 0.05) and MOUD (66.9% to 75.0%, p < 0.01) and decreased perceived treatment barriers (2.1 to 1.9, p < 0.01); desire to quit all substances increased (7.2 to 7.8, p = 0.05). Self-reported opioid use was significantly decreased at each follow-up (all p < 0.01). Self-reported overdose-risk behaviors decreased significantly (6.2 to 2.4, p < 0.01). A majority of participants (65 %) reported naloxone utilization. CONCLUSIONS: PTOEND may be effective for promoting harm reduction and treatment readiness.
Assuntos
Redução do Dano/efeitos dos fármacos , Naloxona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Overdose de Opiáceos/prevenção & controle , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Medicina de Precisão/métodos , Adulto , Analgésicos Opioides/farmacologia , Analgésicos Opioides/uso terapêutico , Feminino , Seguimentos , Redução do Dano/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Overdose de Opiáceos/psicologia , Transtornos Relacionados ao Uso de Opioides/psicologia , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Educação de Pacientes como Assunto/métodos , Medicina de Precisão/psicologiaRESUMO
INTRODUCTION: Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV prevalence remains around 40% among people who inject drugs (PWID). New direct-acting antiviral (DAA) HCV therapies combine high cure rates (>90%) and short treatment duration (8 to 12 weeks). Theoretical mathematical modelling evidence suggests HCV treatment scale-up can prevent transmission and substantially reduce HCV prevalence/incidence among PWID. Our primary aim is to generate empirical evidence on the effectiveness of HCV 'Treatment as Prevention' (TasP) in PWID. METHODS AND ANALYSIS: We plan to establish a natural experiment with Tayside, Scotland, as a single intervention site where HCV care pathways are being expanded (including specialist drug treatment clinics, needle and syringe programmes (NSPs), pharmacies and prison) and HCV treatment for PWID is being rapidly scaled-up. Other sites in Scotland and England will act as potential controls. Over 2 years from 2017/2018, at least 500 PWID will be treated in Tayside, which simulation studies project will reduce chronic HCV prevalence among PWID by 62% (from 26% to 10%) and HCV incidence will fall by approximately 2/3 (from 4.2 per 100 person-years (p100py) to 1.4 p100py). Treatment response and re-infection rates will be monitored. We will conduct focus groups and interviews with service providers and patients that accept and decline treatment to identify barriers and facilitators in implementing TasP. We will conduct longitudinal interviews with up to 40 PWID to assess whether successful HCV treatment alters their perspectives on and engagement with drug treatment and recovery. Trained peer researchers will be involved in data collection and dissemination. The primary outcome - chronic HCV prevalence in PWID - is measured using information from the Needle Exchange Surveillance Initiative survey in Scotland and the Unlinked Anonymous Monitoring Programme in England, conducted at least four times before and three times during and after the intervention. We will adapt Bayesian synthetic control methods (specifically the Causal Impact Method) to generate the cumulative impact of the intervention on chronic HCV prevalence and incidence. We will use a dynamic HCV transmission and economic model to evaluate the cost-effectiveness of the HCV TasP intervention, and to estimate the contribution of the scale-up in HCV treatment to observe changes in HCV prevalence. Through the qualitative data we will systematically explore key mechanisms of TasP real world implementation from provider and patient perspectives to develop a manual for scaling up HCV treatment in other settings. We will compare qualitative accounts of drug treatment and recovery with a 'virtual cohort' of PWID linking information on HCV treatment with Scottish Drug treatment databases to test whether DAA treatment improves drug treatment outcomes. ETHICS AND DISSEMINATION: Extending HCV community care pathways is covered by ethics (ERADICATE C, ISRCTN27564683, Super DOT C Trial clinicaltrials.gov: NCT02706223). Ethical approval for extra data collection from patients including health utilities and qualitative interviews has been granted (REC ref: 18/ES/0128) and ISCRCTN registration has been completed (ISRCTN72038467). Our findings will have direct National Health Service and patient relevance; informing prioritisation given to early HCV treatment for PWID. We will present findings to practitioners and policymakers, and support design of an evaluation of HCV TasP in England.
Assuntos
Antivirais/administração & dosagem , Controle de Doenças Transmissíveis , Redução do Dano/efeitos dos fármacos , Hepacivirus/efeitos dos fármacos , Hepatite C Crônica , Abuso de Substâncias por Via Intravenosa , Controle de Doenças Transmissíveis/economia , Controle de Doenças Transmissíveis/métodos , Análise Custo-Benefício , Transmissão de Doença Infecciosa/prevenção & controle , Monitoramento de Medicamentos/métodos , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/etiologia , Hepatite C Crônica/prevenção & controle , Humanos , Incidência , Ensaios Clínicos Controlados Aleatórios como Assunto , Escócia/epidemiologia , Abuso de Substâncias por Via Intravenosa/complicações , Abuso de Substâncias por Via Intravenosa/epidemiologiaRESUMO
This article outlines a liberation-focused model of addiction treatment. Drawing on the Latin root word "addictus", addiction is seen as slavery and freedom, rather than the cessation of drug and alcohol use, is proposed as a viable, alternative treatment goal. Freedom is defined as: (1) the capacity to create a life of social and internal complexity and multiplicity; (2) the ability to make choices from an array of options; and (3) the possibility of engaging in long-term, goal-directed behavior. This vision of personal liberation is then embedded within a biopsychosocial model of care and treatment. Examples of how biomedical, psychological, and social interventions can each serve to promote the goal and experience of freedom and liberation are provided. Engaging in identity projects and using harm reduction interventions and philosophies are also seen as key to this transformative journey.
Assuntos
Comportamento Aditivo/terapia , Transtornos Relacionados ao Uso de Substâncias/terapia , Liberdade , Redução do Dano/efeitos dos fármacos , Humanos , Motivação/efeitos dos fármacosRESUMO
Smokers who inaccurately believe that FDA evaluates cigarettes for safety hold lower harm perceptions of cigarettes compared to those who do not hold this belief. However, not much is known about associations between beliefs about FDA tobacco regulatory authority and comparative harm perceptions of tobacco products. Data were analyzed from the Health Information National Trends Survey, HINTS-FDA 2015 (Nâ¯=â¯3738), which is a cross-sectional, probability-based, nationally representative survey of U.S. non-institutionalized civilian adults aged 18â¯years or older. Weighted multinomial and logistic regression analyses regressed comparative harm perceptions on sociodemographic factors, beliefs about FDA regulatory authority, perceptions of FDA credibility, and beliefs about modifiability of cancer risk (behavioral cancer causal beliefs and cancer fatalism). Findings indicate that, compared to non-users, current tobacco users are more likely to report believing that e-cigarettes are less harmful than cigarettes, to report believing that some cigarette types may be less harmful than others, and to report believing that tobacco products are safer now than they were five years ago. Awareness of FDA regulatory authority was associated with reporting the belief that tobacco products are safer now than five years ago, that e-cigarettes are less harmful than cigarettes, and that some cigarette types are less harmful than other cigarette types. Believing behavior as a cause of cancer and endorsing cancer fatalism were associated with uncertainty of comparative harm perceptions. Communication efforts can help target inaccurate beliefs by raising awareness about regulation of tobacco products as well as the risks of tobacco products.
Assuntos
Conscientização , Redução do Dano/efeitos dos fármacos , Neoplasias , Produtos do Tabaco/legislação & jurisprudência , United States Food and Drug Administration/legislação & jurisprudência , Adulto , Estudos Transversais , Feminino , Inquéritos Epidemiológicos , Humanos , Masculino , Neoplasias/epidemiologia , Neoplasias/etiologia , Fatores de Risco , Fumar/efeitos adversos , Produtos do Tabaco/efeitos adversos , Estados Unidos/epidemiologiaRESUMO
This paper examines overdose prevention programs based on peer administration of the opioid antagonist naloxone. The data for this study consist of 40 interviews and participant observation of 10 overdose prevention training sessions at harm reduction agencies in the Bronx, New York, conducted between 2010 and 2012. This paper contends that the social logic of peer administration is as central to the success of overdose prevention as is naloxone's pharmacological potency. Whereas prohibitionist drug policies seek to isolate drug users from the spaces and cultures of drug use, harm reduction strategies like peer-administered naloxone treat the social contexts of drug use as crucial resources for intervention. Such programs utilize the expertise, experience, and social connections gained by users in their careers as users. In revaluing the experience of drug users, naloxone facilitates a number of harm reduction goals. But it also raises complex questions about responsibility and risk. This paper concludes with a discussion of how naloxone's social logic illustrates the contradictions within broader neoliberal trends in social policy.
Assuntos
Usuários de Drogas/psicologia , Redução do Dano/efeitos dos fármacos , Grupo Associado , Política Pública/tendências , Overdose de Drogas/tratamento farmacológico , Overdose de Drogas/prevenção & controle , Usuários de Drogas/educação , Humanos , Naloxona/administração & dosagem , Naloxona/uso terapêutico , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/uso terapêutico , Apoio Social , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/psicologiaRESUMO
Nalmefene was the first treatment approved by the European Medicines Agency for reducing alcohol consumption in adult patients with alcohol dependence. It is often presented as a paradigm shift in therapeutics, but major issues limit the interpretation of the evidence supporting its use. The randomised trials submitted provided no evidence of harm reduction, the differences on consumption outcomes were of questionable clinical relevance, the target population was defined a posteriori and the drug was compared to a placebo although naltrexone was already used off-label. No post-approval randomised study is currently designed to clearly address these issues. In addition, nalmefene trials have been uncritically cited, even in guidelines. This experience reveals weaknesses in drug evaluations in alcohol dependence, which call for changes. We propose to dispense with alcohol consumption as a surrogate outcome, to consider comparative effectiveness issues, and to recommend randomised post-approval studies in case of controversial approval.
Assuntos
Abstinência de Álcool , Alcoolismo/diagnóstico , Alcoolismo/tratamento farmacológico , Naltrexona/análogos & derivados , Adulto , Consumo de Bebidas Alcoólicas/tratamento farmacológico , Consumo de Bebidas Alcoólicas/epidemiologia , Alcoolismo/epidemiologia , Feminino , Redução do Dano/efeitos dos fármacos , Humanos , Masculino , Naltrexona/farmacologia , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/farmacologia , Antagonistas de Entorpecentes/uso terapêuticoRESUMO
A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that the needs of tobacco users are met. This paper compares the first-line smoking cessation medications with (1) two variants of these existing products: new galenic formulations of varenicline and novel nicotine delivery devices; and (2) 24 alternative products: cytisine (novel outside Central and Eastern Europe), nortriptyline, other tricyclic antidepressants, electronic cigarettes, clonidine (an anxiolytic), other anxiolytics (e.g. buspirone), selective serotonin reuptake inhibitors, supplements (e.g. St John's wort), silver acetate, Nicobrevin, modafinil, venlafaxine, monoamine oxidase inhibitors (MAOIs), opioid antagonists, nicotinic acetylcholine receptor (nAChR) antagonists, glucose tablets, selective cannabinoid type 1 receptor antagonists, nicotine vaccines, drugs that affect gamma-aminobutyric acid (GABA) transmission, drugs that affect N-methyl-D-aspartate (NMDA) receptors, dopamine agonists (e.g. levodopa), pioglitazone (Actos; OMS405), noradrenaline reuptake inhibitors and the weight management drug lorcaserin. Six 'ESCUSE' criteria-relative efficacy, relative safety, relative cost, relative use (overall impact of effective medication use), relative scope (ability to serve new groups of patients) and relative ease of use-are used. Many of these products are in the early stages of clinical trials; however, cytisine looks most promising in having established efficacy and safety with low cost. Electronic cigarettes have become very popular, appear to be efficacious and are safer than smoking, but issues of continued dependence and possible harms need to be considered.
Assuntos
Redução do Dano/efeitos dos fármacos , Agonistas Nicotínicos/uso terapêutico , Abandono do Hábito de Fumar/métodos , Fumar/tratamento farmacológico , HumanosRESUMO
BACKGROUND: Alcohol dependence causes considerable harm to patients. Treatment with nalmefene, aiming to reduce consumption rather than maintain complete abstinence, has been licensed based on trials demonstrating a reduction in total alcohol consumption and heavy drinking days. Relating these trial outcomes to harmful events avoided is important to demonstrate the clinical relevance of nalmefene treatment. METHODS: A predictive microsimulation model was developed to compare nalmefene plus brief psychosocial intervention (BRENDA) versus placebo plus BRENDA for the treatment of patients with alcohol dependence and a high or very high drinking risk level based on three pooled clinical trials. The model simulated patterns and level of alcohol consumption, day-by-day, for 12 months, to estimate the occurrence of alcohol-attributable diseases, injuries and deaths; assessing the clinical relevance of reducing alcohol consumption with treatment. RESULTS: The microsimulation model predicted that, in a cohort of 100,000 patients, 971 (95 % confidence interval [CI] 904-1038) alcohol-attributable diseases and injuries and 133 (95 % CI 117-150) deaths would be avoided with nalmefene versus placebo. This level of benefit has been considered clinically relevant by the European Medicines Agency. CONCLUSIONS: This microsimulation model supports the clinical relevance of the reduction in alcohol consumption, and has estimated the extent of the public health benefit of treatment with nalmefene in patients with alcohol dependence and a high or very high drinking risk level.
Assuntos
Consumo de Bebidas Alcoólicas/tratamento farmacológico , Alcoolismo/tratamento farmacológico , Naltrexona/análogos & derivados , Saúde Pública/métodos , Apoio Social , Consumo de Bebidas Alcoólicas/efeitos adversos , Consumo de Bebidas Alcoólicas/psicologia , Alcoolismo/complicações , Alcoolismo/psicologia , Ensaios Clínicos como Assunto/estatística & dados numéricos , Simulação por Computador , Europa (Continente) , Redução do Dano/efeitos dos fármacos , Humanos , Estudos Multicêntricos como Assunto/estatística & dados numéricos , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Avaliação de Processos e Resultados em Cuidados de Saúde/estatística & dados numéricos , Saúde Pública/estatística & dados numéricosRESUMO
Purpose - The environmental and demographic characteristics of closed institutions, particularly prisons, precipitate morbidity during hepatitis A virus (HAV) outbreaks. Given the high prevalence of chronic liver disease and other risk factors in the prison setting, the purpose of this paper is to examine HAV-immunity and its associated factors in this population. Design/methodology/approach - The cross-sectional study was conducted in 2009: a serology screening for HAV IgG was carried out among 116 inmates in Switzerland's largest pre-trial prison. Other participant characteristics were collected through a structured face-to-face questionnaire with a physician. Findings - In terms of significant demographics, Africa (53.5 percent) and the Balkans/Eastern Europe (36.2 percent) were the main regions of origin; a minority of inmates were from Western Europe (6.9 percent), Latin America (2.6 percent) or Asia (0.9 percent). The authors identified hepatitis A antibody-negative serology (lack of immunity) in five out of 116 prisoners (4.3 percent, 95 percent CI 1.4-9.7). Among participants of European origin alone, five out of 50 inmates were hepatitis A antibody-negative (10 percent, 95 percent CI 3.3-21.8), whereas the 66 inmates from other all continents were hepatitis A antibody-positive (immune) (p=0.026). Originality/value - In this prison population composed of mostly African migrants, hepatitis A immunity was high. This reaffirms that region of origin is highly associated with childhood immunity against HAV. HAV vaccination should take into account a patient's area of origin and his/her risk factors for systemic complications, if ever infected. This targeted strategy would offer herd immunity, and seek out the most vulnerable individuals who are potentially at risk of new exposure in this precarious setting.
Assuntos
Vacinas contra Hepatite A/administração & dosagem , Hepatite A/etnologia , Prisioneiros/estatística & dados numéricos , Adulto , População Negra/estatística & dados numéricos , Estudos Transversais , Emigrantes e Imigrantes/estatística & dados numéricos , Redução do Dano/efeitos dos fármacos , Nível de Saúde , Hepatite A/sangue , Hepatite A/imunologia , Anticorpos Anti-Hepatite A/sangue , Anticorpos Anti-Hepatite A/imunologia , Vacinas contra Hepatite A/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Soroepidemiológicos , Suíça/epidemiologia , Adulto JovemRESUMO
Neurotoxicity is considered as a major cause of neurodegenerative disorders. Most drugs of abuse have nonnegligible neurotoxic effects many of which are primarily mediated by several dopaminergic and glutamatergic neurotransmitter systems. Although many researchers have investigated the medical and cognitive consequences of drug abuse, the neurotoxicity induced by these drugs still requires comprehensive attention. The science of neurotoxicity promises to improve preventive and therapeutic strategies for brain disorders such as Alzheimer disease and Parkinson's disease. However, its clinical applications for addiction medicine remain to be defined adequately. This chapter reviews the most commonly discussed mechanisms underlying neurotoxicity induced by common drugs of abuse including amphetamines, cocaine, opiates, and alcohol. In addition, the known factors that trigger and/or predispose to drug-induced neurotoxicity are discussed. These factors include drug-related, individual-related, and environmental insults. Moreover, we introduce some of the potential pharmacological antineurotoxic interventions deduced from experimental animal studies. These interventions involve various targets such as dopaminergic system, mitochondria, cell death signaling, and NMDA receptors, among others. We conclude the chapter with a discussion of addicted patients who might benefit from such interventions.
Assuntos
Doença de Alzheimer/prevenção & controle , Dopamina/metabolismo , Redução do Dano/fisiologia , Mitocôndrias/metabolismo , Síndromes Neurotóxicas/prevenção & controle , Doença de Parkinson/prevenção & controle , Doença de Alzheimer/complicações , Doença de Alzheimer/tratamento farmacológico , Animais , Dopamina/farmacologia , Redução do Dano/efeitos dos fármacos , Humanos , Síndromes Neurotóxicas/tratamento farmacológico , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológicoAssuntos
Atitude Frente a Saúde , Redução do Dano/fisiologia , Transtornos Mentais , Abandono do Hábito de Fumar/métodos , Fumar/terapia , Dispositivos para o Abandono do Uso de Tabaco/estatística & dados numéricos , Adolescente , Adulto , Comorbidade , Feminino , Redução do Dano/efeitos dos fármacos , Promoção da Saúde , Humanos , Masculino , Transtornos Mentais/epidemiologia , Pessoa de Meia-Idade , Fumar/epidemiologia , Adulto JovemRESUMO
Estudo descritivo qualitativo com perspectiva sócio-histórica, que analisa como a política de Redução de Danos se desenvolveu enquanto estratégia de prevenção e cuidado do HIV/AIDS entre os usuários de drogas injetáveis no município de Florianópolis-SC. Foram realizadas entrevistas utilizando a técnica de História Oral Temática. Os sujeitos do estudo foram dez profissionais de saúde que exerceram atividades de assistência e/ou gestão vinculadas as DST/AIDS no período do estudo (1993-2010). Para tratamento dos dados utilizou-se análise de conteúdo, chegando a duas categorias: A implantação do Projeto de Redução de Danos em Florianópolis; e O reconhecimento da Redução de Danos como política estratégica de prevenção ao HIV e outras situações de vulnerabilidade. Como resultados, destaca-se neste município aspectos desta política inclusiva e inovadora no cuidado em saúde, ao colocar em prática princípios substantivos do SUS entre usuários de drogas, gerando novas possibilidades de prevenção e cuidado entre esta população.
This descriptive qualitative study was performed with a socio-historical perspective, and analyzes how the Harm Reduction policy was developed as a strategy for HIV/AIDS prevention and care among injectable drug users in the municipality of Florianópolis-Santa Catarina state. Interviews were performed using the Thematic Oral History technique. The subjects were ten health care professionals working with health care and/or management activities related to STD/AIDS during the period of the study (1993-2010). Content analysis was used, resulting in two categories: The implementation of the Harm Reduction Project in Florianópolis; and Recognizing Harm Reduction as a strategic policy for the prevention of HIV and other situations of vulnerability. The main results, in the referred municipality, were aspects of this inclusive and innovative policy in health care, by practicing central principles of the Unified Health System (SUS) among drug users, thus generating new possibilities for the prevention and care among this population.
Estudio descriptivo, cualitativo, con perspectiva socio-histórica, analizando cómo la política de Reducción de Deterioros se desarrolló en carácter de estrategia de prevención y cuidado del HIV/SIDA entre usuarios de drogas inyectables en el municipio de Florianópolis-SC. Se realizaron entrevistas utilizando la técnica de Historia Oral Temática. Los sujetos de estudio fueron diez profesionales de salud que ejercieron actividades de atención y/o gestión vinculadas a las ETS/SIDA en el período estudiado (1993-2010). Datos tratados por análisis de contenido, conformándose dos categorías: Implantación del Proyecto de Reducción de Deterioros en Florianópolis; y Reconocimiento de la Reducción de Deterioros como política estratégica de prevención del HIV y otras situaciones de vulnerabilidad. Como resultados, se destacan en este municipio, aspectos de esta política inclusiva e innovadora en el cuidado en salud, al poner en práctica principios sustantivos del SUS entre usuarios de drogas, generando nuevas posibilidades de prevención y cuidado entre esta población.
Assuntos
Humanos , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Usuários de Drogas , Redução do Dano/efeitos dos fármacosRESUMO
Nicotine replacement therapy (NRT) has been used in the treatment of tobacco dependence for over three decades. Whilst the choice of NRT was limited early on, in the last ten years there has been substantial increase in the number of nicotine delivery devices that have become available. This article briefly summarises existing forms of NRT, evidence of their efficacy and use, and reviews the rationale for the development of novel products delivering nicotine via buccal, transdermal or pulmonary routes (including nicotine mouth spray, nicotine films, advanced nicotine inhalers and electronic cigarettes). It presents available evidence on the efficacy, tolerability and abuse potential of these products, with a focus on their advantages as well as disadvantages compared with established forms of NRT for use as an aid to both smoking cessation as well as harm reduction.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Redução do Dano/efeitos dos fármacos , Nicotina/administração & dosagem , Abandono do Hábito de Fumar/métodos , Fumar/tratamento farmacológico , Sistemas de Liberação de Medicamentos/tendências , Redução do Dano/fisiologia , Humanos , Fumar/epidemiologiaRESUMO
PROBLEM: In Malaysia, human immunodeficiency virus (HIV) infection is highly concentrated among people who inject opioids. For this reason, the country undertook a three-phase roll-out of a methadone maintenance treatment (MMT) programme. In Phase 3, described in this paper, MMT was implemented within prisons and retention in care was assessed. APPROACH: After developing standard operating procedures and agreement between its Prisons Department and Ministry of Health, Malaysia established pilot MMT programmes in two prisons in the states of Kelantan (2008) and Selangor (2009) - those with the highest proportions of HIV-infected prisoners. Community-based MMT programmes were also established in Malaysia to integrate treatment activities after prisoners' release. LOCAL SETTING: Having failed to reduce the incidence of HIV infection, in 2005 Malaysia embarked on a harm reduction strategy. RELEVANT CHANGES: STANDARD OPERATING PROCEDURES WERE MODIFIED TO: (i) escalate the dose of methadone more slowly; (ii) provide ongoing education and training for medical and correctional staff and inmates; (iii) increase the duration of methadone treatment before releasing prisoners; (iv) reinforce linkages with community MMT programmes after prisoners' release; (v) screen for and treat tuberculosis; (vi) escalate the dose of methadone during treatment for HIV infection and tuberculosis; and (vii) optimize the daily oral dose of methadone (> 80 mg) before releasing prisoners. LESSONS LEARNT: Prison-based MMT programmes can be effectively implemented but require adequate dosing and measures are needed to improve communication between prison and police authorities, prevent police harassment of MMT clients after their release, and improve systems for tracking release dates.
Assuntos
Infecções por HIV/transmissão , Metadona/uso terapêutico , Tratamento de Substituição de Opiáceos/métodos , Prisões/tendências , Abuso de Substâncias por Via Intravenosa/reabilitação , Adulto , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Redução do Dano/efeitos dos fármacos , Implementação de Plano de Saúde , Humanos , Malásia/epidemiologia , Masculino , Metadona/administração & dosagem , Tratamento de Substituição de Opiáceos/tendências , Abuso de Substâncias por Via Intravenosa/complicaçõesRESUMO
BACKGROUND: Psychotic symptoms are common among cocaine users. METHODS: An observational naturalistic study on the effects and events of intravenous cocaine use in a drug consumption room was carried out; the patients were diagnosed of cocaine dependence (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision). RESULTS: Twenty-one patients, 81% men self-injected cocaine 375 times. Psychotic symptoms were observed in 62% of the patients and 21% of the self-injections; delusions were observed in 9.3%, psychotic self-reference with insight in 9.1%, illusions in 6.4%, and hallucinations in 5.3%. A higher presence of psychotic symptoms was noted with cannabis used in the previous month (76.9% versus 44.4%; P = .001) (no psychotic symptoms group); also, a greater use of benzodiazepines was observed: 75.6% versus 63.6% (P = .046). Lower use of methadone in the group with psychosis was observed: 75.6% versus 97.3% (P = .001). Motor alterations were tremor 58%, stereotyped movements 24%, and behaviour alteration 6%, significantly more frequent in the psychotic group. CONCLUSIONS: Thus, there was a high frequency of psychotic symptoms after intravenous cocaine use; patients with psychotic symptoms reported higher use of cannabis and benzodiazepines in the previous month and lower use of methadone. More tremors and stereotyped movements were observed in the group with psychotic symptoms. It is necessary to give a special approach to cocaine intravenous users.
Assuntos
Cocaína/efeitos adversos , Redução do Dano/efeitos dos fármacos , Psicoses Induzidas por Substâncias/diagnóstico , Administração Intravenosa , Adulto , Cocaína/administração & dosagem , Transtornos Relacionados ao Uso de Cocaína/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psicoses Induzidas por Substâncias/complicações , AutomedicaçãoRESUMO
Risk avoidance is an important determinant of human behavior. The neurotransmitter serotonin has been implicated in processing negative outcomes caused by risky decisions. However, it is unclear whether serotonin provides a neurobiological link between making a risk aversive decision and the response to a negative outcome. Using pharmacological fMRI, we manipulated the availability of serotonin in healthy volunteers while performing a gambling task. The same group of participants was studied in three fMRI sessions: (i) during intravenous administration of the SSRI citalopram to increase the serotonergic tone, (ii) after acute tryptophan depletion (ATD) to reduce central serotonin levels, or (iii) without interventions. ATD and citalopram had opposite effects on outcome related activity in dorsomedial prefrontal cortex (dmPFC) and amygdala. Relative to the control condition, ATD increased and citalopram decreased the neural response to negative outcomes in dmPFC. Conversely, ATD decreased and citalopram increased the neural response to negative outcomes in left amygdala. Critically, these pharmacological effects were restricted to negative outcomes that were caused by low-risk decisions and led to a high missed reward. ATD and citalopram did not alter the neural response to positive outcomes in dmPFC, but relative to ATD, citalopram produced a bilateral increase in the amygdala response to large wins caused by high-risk choices. The results show a selective involvement of the serotonergic system in neocortical processing of negative outcomes resulting from risk-averse decisions, thereby linking risk aversion and processing of negative outcomes in goal-directed behaviors.
Assuntos
Retroalimentação Fisiológica , Córtex Pré-Frontal/metabolismo , Assunção de Riscos , Neurônios Serotoninérgicos/metabolismo , Serotonina/fisiologia , Transmissão Sináptica , Adulto , Tonsila do Cerebelo/efeitos dos fármacos , Tonsila do Cerebelo/metabolismo , Mapeamento Encefálico , Comportamento de Escolha/efeitos dos fármacos , Dinamarca , Retroalimentação Fisiológica/efeitos dos fármacos , Feminino , Jogo de Azar , Redução do Dano/efeitos dos fármacos , Humanos , Imageamento por Ressonância Magnética , Masculino , Córtex Pré-Frontal/efeitos dos fármacos , Recompensa , Neurônios Serotoninérgicos/efeitos dos fármacos , Inibidores Seletivos de Recaptação de Serotonina/farmacologia , Transmissão Sináptica/efeitos dos fármacos , Triptofano/antagonistas & inibidores , Triptofano/metabolismoRESUMO
INTRODUCTION: Because of the increasing number of injecting drug users (IDUs) in Iran and the risk of the spread of HIV infection, harm reduction programs have been considered for conventional law enforcement measures. The aim of this study was to evaluate the efficacy of methadone maintenance therapy (MMT) in IDUs and the associated health and social outcomes. MATERIAL AND METHODS: This case-control study was conducted at the Persepolis Harm Reduction Center in Tehran during the year 2006. Data were gathered from two groups of randomly chosen patients. The first group consisted of 75 IDU patients who had undergone at least 6 months of methadone treatment (the MMT group), and second group consisted of 75 newly admitted clients (the control group). Participants were assessed on their dangerous injection and sexual behaviors, social well-being, and patterns of drug use. The results were compared between the two groups. RESULTS: The mean age of participants in the two groups was almost the same (34.28 years in the control group and 35.68 years in the MMT group, p >.05). Prevalence of drug injection in the MMT group was less than that in the control group (16% vs. 100%). There was also a dramatic difference in needle and syringe sharing (40% in the control group vs. 4% in the MMT group) but not in crimes and arrests (p = .4). Those in the MMT group had a better relationship with their families, partners, coworkers, and neighbors compared with controls. There was no considerable difference in dangerous sexual behaviors between the two groups. CONCLUSIONS: Given the large number of HIV-positive cases among IDUs and considering that injection drug use is the main spreading factor for HIV, MMT would play a major role in controlling the HIV epidemic through reduction of heroin injection and the risk behaviors related to it. High inflation rate, lack of interorganization coordination, budget limitation, and no follow-up were the most important limitations of this study.
Assuntos
Metadona/uso terapêutico , Tratamento de Substituição de Opiáceos/psicologia , Abuso de Substâncias por Via Intravenosa/tratamento farmacológico , Abuso de Substâncias por Via Intravenosa/psicologia , Adaptação Psicológica/efeitos dos fármacos , Adulto , Estudos de Casos e Controles , Crime/psicologia , Crime/estatística & dados numéricos , Infecções por HIV/prevenção & controle , Redução do Dano/efeitos dos fármacos , Humanos , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Uso Comum de Agulhas e Seringas/estatística & dados numéricos , Tratamento de Substituição de Opiáceos/métodos , Prevalência , Comportamento Sexual/efeitos dos fármacos , Comportamento Sexual/psicologia , Comportamento Social , Abuso de Substâncias por Via Intravenosa/epidemiologia , Transtornos Relacionados ao Uso de Substâncias , Sexo sem Proteção/psicologia , Sexo sem Proteção/estatística & dados numéricosRESUMO
Buprenorphine/naloxone has recently been introduced in Australia and is available for unsupervised dosing within Queensland. A retrospective observational study of data collected during 2000-2007 for clients obtaining injecting equipment from the Brisbane Harm Reduction Centre in Queensland is presented. The numbers of service occasions and needles and syringes were used as surrogate drug use measures. Buprenorphine and naloxone were misused at lower rates when compared with buprenorphine and methadone. Furthermore, the misuse of opioid replacement therapies represented less than 5% of all illicit opioid injections. Implications and study limitations are discussed.
Assuntos
Analgésicos Opioides/uso terapêutico , Buprenorfina/uso terapêutico , Metadona/uso terapêutico , Naloxona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Tratamento de Substituição de Opiáceos/métodos , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Combinação de Medicamentos , Redução do Dano/efeitos dos fármacos , Humanos , Queensland , Estudos Retrospectivos , Abuso de Substâncias por Via Intravenosa/tratamento farmacológico , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológicoRESUMO
Although selective serotonin reuptake inhibitors (SSRI) are generally effective in reducing impulsive aggression in individuals with intermittent explosive disorder, a large proportion of intermittent explosive disorder patients fail to achieve full remission despite adequate dosage and duration of treatment. Temperament, specifically those associated with negative emotionality (neuroticism, harm avoidance) may predict response to SSRI treatment. The objective of this study was to determine whether baseline neuroticism and harm avoidance scores would be associated with reduced aggression (as measured by the Overt Aggression Scale-Modified [OAS-M] aggression scores) after SSRI treatment. Participants participating in a randomized, placebo-controlled clinical trial of fluoxetine completed the Eysenck Personality Questionnaire (n=57) and the Tridimensional Personality Questionnaire (n=38) before entering the treatment trial. Multiple regression analyses (accounting for baseline OAS-M aggression scores) revealed that pretreatment eysenck personality questionnaire neuroticism and tridimensional personality questionnaire harm avoidance independently and uniquely predicted OAS-M aggression scores at endpoint in the fluoxetine, but not placebo, treated group. These preliminary findings are the first from a placebo-controlled clinical trial to suggest that temperamental factors such as neuroticism and harm avoidance can partly explain the observed variability in treatment response in SSRI treated individuals with impulsive aggression and prompt future prospective studies examining personality dimensions as predictors of outcomes in clinical trials.